|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
myalgia |
|
nausea |
|
pain |
|
Abdominal pain |
|
ataxia |
|
chest pain |
|
decreased hearing |
|
dizziness |
|
dyspnea |
|
hypersensitivity reaction |
|
injection-site reactions |
|
mental depression, especially with suicidal ideation |
|
muscle spasms |
|
nevi |
|
ovarian cyst |
|
seizures |
|
speech problems |
|
syncope |
|
upper respiratory infection |
|
urticaria |
|
vaginitis |
|
vasodilation |
|
Anorexia |
|
herpes simplex |
|
herpes zoster |
|
malaise |
|
otitis media |
|
sinusitis |
|
Dyspepsia |
|
Alopecia |
|
insomnia |
|
Anemia |
|
asthenia |
|
diarrhea |
|
infection |
|
influenza-like syndrome including arthralgia |
|
chills |
|
fever |
|
headache |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiac disease |
|
Angina |
|
Arrhythmias |
|
Congestive heart failure |
|
>> Depression, mental, especially with suicidal ideation |
|
>> Seizure disorder |
|
|
ADULT DOSE:
|
|
Multiple sclerosis, relapsing-remitting -
Avonex:Intramuscular, 30 mcg once a week .
Rebif:Subcutaneous, 22 mcg 3 times per week. Patients with an EDSS of 4 or higher may require a dose of 44 mcg 3 times per week.
Condyloma acuminatum-
Rebif:Intra- or peri-lesional, 3.67 mcg (1 million IU) per lesion 3 times per week for 3 weeks |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy in children up to 18 years of age have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|